High risk Myelodysplastic syndrome (MDS)
Showing 1 - 25 of >10,000
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial in Worldwide (HDM201, MBG453, Venetoclax)
Active, not recruiting
- Acute Myeloid Leukemia (AML)
- High-risk Myelodysplastic Syndrome (MDS)
- HDM201
- +2 more
-
Durham, North Carolina
- +8 more
Dec 13, 2022
Leukemia Trial in Houston (Cladribine, Cytarabine, Decitabine)
Recruiting
- Leukemia
- Cladribine
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Aug 23, 2022
Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia Trial
Recruiting
- Recurrent Chronic Myelomonocytic Leukemia
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Jul 21, 2022
Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome Trial in
Recruiting
- Acute Myeloid Leukemia
- +7 more
- Cladribine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 7, 2022
Myelodysplastic Syndrome (MDS) Trial in Worldwide (sabatolimab, azacitidine, venetoclax)
Active, not recruiting
- Myelodysplastic Syndrome (MDS)
- sabatolimab
- +2 more
-
Brasschaat, Belgium
- +9 more
Jan 19, 2023
MDS Trial (Decitabine/Cedazuridine, Magrolimab)
Not yet recruiting
- Myelodysplastic Syndromes
- (no location specified)
Apr 18, 2023
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Trial in Houston (Decitabine and Cedazuridine, Venetoclax)
Recruiting
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Decitabine and Cedazuridine
- Venetoclax
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Suzhou
Recruiting
- Allogeneic Hematopoietic Stem Cell Transplantation
- +2 more
- VEN+AZA+Modified BUCY
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Apr 10, 2023
Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Houston (Nivolumab, Idarubicin, Cytarabine)
Completed
- Leukemia
- +2 more
- Nivolumab
- +4 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 9, 2021
Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial
Completed
- Relapsed Acute Myeloid Leukemia (AML)
- +2 more
-
Atlanta, Georgia
- +5 more
Apr 4, 2022
Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in United States (Milademetan, AZA)
Terminated
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
-
Duarte, California
- +4 more
Sep 14, 2021
MDS Trial in Worldwide (MBG453, Placebo, Hypomethylating agents)
Active, not recruiting
- Myelodysplastic Syndromes
- MBG453
- +2 more
-
Duarte, California
- +46 more
Jan 20, 2023
High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,
Active, not recruiting
- High Risk Myelodysplastic Syndrome
- +2 more
- Azacitidine
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Aug 11, 2022
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk
Recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +5 more
- Gemtuzumab Ozogamicin
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Leukemia, Acute, AML, Adult, ALL, Adult Trial in Charlottesville (Palliative Care Visits)
Recruiting
- Leukemia, Acute
- +3 more
- Palliative Care Visits
-
Charlottesville, VirginiaUniversity of Virginia
Apr 28, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte (procedure, drug, biological, other)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Allogeneic Hematopoietic Stem Cell Transplantation
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Apr 10, 2023
Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning Trial in Guangzhou (Granulocyte
Recruiting
- Myelodysplastic Syndrome
- +2 more
- Granulocyte Colony-Stimulating Factor(G-CSF)
- +5 more
-
Guangzhou, Guangdong, ChinaDepartment of Hematology,Nanfang Hospital, Southern Medical Univ
Jul 11, 2022
MDS (MDS), Acute Myelogenous Leukemia (AML) Trial in United States (low dose 5'-azacitidine)
Active, not recruiting
- Myelodysplastic Syndromes (MDS)
- Acute Myelogenous Leukemia (AML)
- low dose 5'-azacitidine
-
Basking Ridge, New Jersey
- +6 more
Dec 1, 2022
MDS, Acute Myeloid Leukemia Trial in Australia, France, Germany (Imetelstat)
Not yet recruiting
- Myelodysplastic Syndromes
- Acute Myeloid Leukemia
-
Adelaide, Australia
- +11 more
Oct 13, 2022
High Risk Myelodysplastic Syndrome Trial in Houston (Guadecitabine)
Active, not recruiting
- High Risk Myelodysplastic Syndrome
-
Houston, TexasM D Anderson Cancer Center
Feb 2, 2022
Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)
Active, not recruiting
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Gemtuzumab Ozogamicin
-
Valhalla, New YorkNew York Medical College
Nov 11, 2021